Skip to main content
padlock icon - secure page this page is secure

c‐Met inhibition enhances chemosensitivity of human ovarian cancer cells

Buy Article:

$52.00 + tax (Refund Policy)

In clinical practice, human ovarian cancer shows considerable resistance to chemotherapy. This study aimed to investigate the role of c‐Met in the chemoresistance of ovarian cancer. Ovarian cancer cell line SKOV3 and OVCAR‐3 were pretreated with c‐Met inhibitor INCB28060, and then treated with paclitaxel. Cell survival, cell cycle and apoptosis were analyzed by MTT assay, flow cytometry analysis and TUNEL assay, respectively. The activation of c‐Met signalling was detected by western blot analysis. INCB28060 inhibited the survival of SKOV3 and OVCAR‐3 cells and enhanced the chemosensitivity of SKOV3 and OVCAR‐3 cells to paclitaxel. INCB28060 inhibited c‐Met signalling, caused mitochondrial membrane depolarization and DNA repair, and induced the apoptosis of SKOV3 and OVCAR‐3 cells. c‐Met plays an important role in mediating the chemoresistance of ovarian cancer. The combination of c‐Met inhibitor and chemotherapy is a promising strategy to human ovarian cancer.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: INCB28060; OVCAR‐3; SKOV3; chemotherapy; c‐Met; ovarian cancer

Document Type: Research Article

Publication date: January 1, 2017

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more